IMR Press / FBS / Volume 3 / Issue 1 / DOI: 10.2741/S134

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Therapeutic advances in women's cancers

Show Less
1 Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, TX 77030
2 Department of Cancer Biology, M.D. Anderson Cancer Center, Houston, TX 77030
3 Center for RNAi and Non-Coding RNA, M.D. Anderson Cancer Center, Houston, TX, 77030

*Author to whom correspondence should be addressed.

Academic Editor: Ronny Drapkin

Front. Biosci. (Schol Ed) 2011, 3(1), 82–97; https://doi.org/10.2741/S134
Published: 1 January 2011
(This article belongs to the Special Issue Advances in gynecologic malignancies)
Abstract

Cytotoxic therapy and surgery have improved outcomes for patients with gynecologic malignancies over the last twenty years, but women's cancers still account for over ten percent of cancer related deaths annually. Insights into the pathogenesis of cancer have led to the development of drugs that target molecular pathways essential to tumor survival including angiogenesis, DNA repair, and apoptosis. This review outlines several of the promising new biologically targeted drugs currently being tested to treat gynecologic malignancies.

Share
Back to top